Pondering Snap’s IPO over laser tag and paintball Even concerns about Snapchat’s slowing user growth aren’t stopping investors from clamoring for its stock.
Snap, the parent company of Snapchat, priced its initial public offering at $17 a share on Wednesday. It had previously proposed a range of $14 to $16 a share.
That will reportedly give Snap a market value of nearly $24 billion, making it the largest U.S. tech IPO since Facebook (FB, Tech30).
Reps for Snap did not immediately respond to a request for comment.
“The demand for the Snap IPO has been very, very strong,” says Jeff Zell, an analyst with IPO Boutique, a research firm. “Even the original naysayers and detractors from the deal have pretty much softened their negativity.”
Top Stocks To Own For 2018: Vitality Biopharma (VBIO)
- [By Jim Robertson]
That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:
- [By James E. Brumley]
Investors who were looking to learn a little more about up-and-coming drug development company Vitality Biopharma Inc (OTCMKTS:VBIO) may want to mark December 8th on their calendar…. if they’re going to be in the Los Angeles area that day anyway. The company will be making a presentation that day, at the annual LD Micro Main Event. Interested and approved investors can attend the VBIO presentation by registering beforehand with LD Micro.
Vitality Biopharma has found a way to make cannabinoid-based pharmaceuticals without the usual downside of cannabinoids. Namely, Vitality Biopharma’s version of cannabinoids are non-psychotropic, meaning larger, more effective dosing is possible without the ‘high’. It’s this little detail that takes cannabinoid medicine — already the most compelling frontier in the world of pharma — to the next level. There’s a reason some people think the cannabinoid market could be worth $20 billion by 2020.
The idea was significantly advanced in early November. In eight of the nine states voters were asked about legalization of marijuana (for one reason or another), voters said yes….. four for recreational use, and four for medical use. In eight of those nine states, the measures passed. Marijuana is legal in more than half the United States now, and we’re en route to a decided majority in the foreseeable future.
VBIO didn’t necessarily need a sweeping victory at the ballot box, but each time marijuana wins, it seems to advance the discussion of the power of cannabinoids as medicine.
Investors will be able to learn more about Vitality Biopharma’s work in that arena on Thursday of this week. On that day — 8 AM PST / 11 AM EST — at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Robert Brooke, CEO of Vitality Biopharma, will be making a presentation as well as meeting with current and prospective investors.
LD Micro was founded in 2006 with the sole purpose of being an independent resource in t
- [By James E. Brumley]
In mid-September, Vitality Biopharma Inc (OTCMKTS:VBIO) announced it was going to take aim at the development of an alternative to opioids as a means of treating pain. At the time, there was little doubt that the company’s cannabinoid science was capable of doing so. What wasn’t clear to VBIO shareholders was exactly how that might happen…. meaning what sort of drug might Vitality Biopharma come up with.
We got the first of what will likely be several answers to the question today. Per today’s press release, Vitality Biopharma intends to come up with a treatment for narcotic bowel syndrome, which is a severe form of (ironically enough) opiate-induced abdominal pain.
As a refresher, Vitality Biopharma was the name we introduced to you back on August 8th, pointing out it had developed a whole new way of making cannabinoid-based medicines. Their versions offer all the upsides of cannabinoids, but without the psychotropic (“getting high’) effects, and without some of the common downsides associated with these pharmaceuticals… like mouth and skin lesions.
There are even bigger advantages to Vitality Biopharma’s science, however. Namely, since these drugs are prodrugs and aren’t activated until in the body, they allow for targeted delivery to the GI tract (yet can also selectively target other body parts, even as far away from the GI tract as the brain). Perhaps more than anything though, these drugs are orally-administered by virtue of being highly soluble, making them easy to use.
It’s this nuance that makes Vitality Biopharma’s recently-announced intention so interesting, and compelling.
Studies have found that up to 81% of patients treated with opiates have functional bowel disorders, with more than half — 58% to be exact — of opiate users reporting chronic abdominal pain stemming from the use of their prescribed painkillers. Considering 200 million opioid prescriptions are filled every year in the United States alo
- [By Phil Saunders]
Vitality Biopharma, Inc. (OTCBB: VBIO) recent ascent as a strong small cap player in Cannabis pharma, is part of a boom in Cannabis-based pharmaceuticals making announcements about unique and innovative delivery systems being tested for such ailments as Epilepsy, Multiple Sclerosis, and Crohns disease. But it is important to understand how the industry is evolving in the United States and Canada and what that might mean when realizing valuation and the evolution of government policies which still vary from jurisdiction to jurisdiction, making access to Cannabis and the pricing model still a big question moving forward.
- [By Matthew Briar]
Back in September, Vitality Biopharma Inc (OTCMKTS:VBIO) CEO Robert Brooke officially announced his company would be entering the painkiller market, specifically taking aim at the development of an alternative to opioids. His specific words? “Opiates are one of the key classes of drugs we’re seeking to replace, or to make far less necessary, as our proprietary cannabosides could provide a potent alternative form of pain relief and help avoid, or greatly reduce, the use of opiates for the treatment of many conditions…”
Top Stocks To Own For 2018: On Assignment Inc.(ASGN)
- [By Jim Robertson]
On Thursday, our Under the Radar Moversnewslettersuggested suggested small cap employment services stockOn Assignment, Inc (NYSE: ASGN) as a short trade thats already turned profitable for us:
Top Stocks To Own For 2018: Technology Select Sector SPDR ETF (XLK)
- [By ]
What My System Flagged As A Buy This Week
It’s no secret that the technology sector has had an incredible year so far — the SPDR Technology Select ETF (NYSE: XLK) is up over 31% year-to-date, compared with the S&P 500’s 14% return.
- [By Craig Jones]
Kevin Kelly, the managing partner at Kelly & Co., spoke on Bloomberg Markets about a bullish options trade in Technology Select Sector SPDR Fund (NYSE: XLK).
- [By Wayne Duggan]
High-flying tech stocks were hammered Wednesday, sending the Technology Select Sector SPDR Fund (NYSE: XLK) down more than 2.5 percent and the Nasdaq down 1.4 percent, its worst day of trading since August 17.
- [By Money Morning News Team]
If the price is keeping you out of GOOGL, take a look at theTechnology SPDR ETF (NYSE Arca: XLK), where you get to hold shares of many of these top tech companies at a fraction of the cost.
Top Stocks To Own For 2018: Dunkin' Brands Group, Inc.(DNKN)
- [By WWW.USATODAY.COM]
While McDonald’s (NYSE: MCD) and Dunkin’ Brands’ (NASDAQ: DNKN) Dunkin’ Donuts both now sell premium espresso-based beverages along with other fancy coffee drinks, people don’t view those brands the way they see Starbucks. The Seattle-based coffee chain exists in its own world, where it can sell out of $10 cups of whisky-barrel-aged coffee while it opens more than a thousand Reserve stores selling pricier drinks than its normal, already expensive beverage lineup.
- [By Ben Levisohn]
Dunkin’ Brands Group (DNKN) has dropped 3.5% to $54.16 after getting cut to Sell from Neutral at Goldman Sachs.
Morgan Stanley (MS) has risen 1.1% to $42.95 after getting upgraded to Buy from Hold at Deutsche Bank.
- [By Ben Levisohn]
The market is treating Chipotle as if it is an Amazon, Tesla, Apple or Google, when in fact all they do is make burritos. With the money it would cost you to buy Chipotle today @ $14 billion dollars you could buy Wendy’s (WEN), Cheesecake Factory (CAKE), Papa John’s International (PZZA), and Dunkin’ Brands (DNKN). Chipotle would need to generate at least $24 in earnings per share in order to justify the current market cap — they are not even expected to generate half of that next year. Chipotle is expected to report Q1 on April 25 and the market, in my opinion, has already more than priced in good news.
- [By John Udovich]
While theMacys Thanksgiving Day parade sponsored by Macy’s, Inc (NYSE:M) is the most well known corporate sponsoredThanksgiving parade,Dunkin Brands Group Inc (NASDAQ:DNKN) and McDonald’s Corporation (NYSE:MCD) also sponsor parades in major USA cities that will help them grab some extra consumer attention and perhaps help the bottom line a bit.
Top Stocks To Own For 2018: Trevena, Inc.(TRVN)
- [By Maxx Chatsko]
Shares of clinical-stage biopharma Trevena (NASDAQ:TRVN) fell nearly 12% today after it reported full-year 2016 earnings. The pre-revenue company didn’t announce any surprises one way or the other. However, investors appear to be considering the near-term consequences of swelling expenses that won’t be offset by product sales anytime soon.
- [By Paul Ausick]
Trevena Inc. (NASDAQ: TRVN) dropped about 6.3% Thursday, to post a new 52-week low of $3.70 after closing at $3.95 on Wednesday. The stock’s 52-week high is $9.73. Volume was nearly 5 times the daily average of around 700,000 shares. The company’s pain-killing drug got mixed results in a trial result reported Tuesday.
- [By Lisa Levin] Gainers
Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than
- [By Lisa Levin]
Trevena Inc (NASDAQ: TRVN) shares dropped 36 percent to $4.55 despite a positive development in Phase 3 trials. Trevena announced positive top-line results from ongoing Phase 3 trials called "APOLLO-1" and "APOLLO-2." The studies evaluated the safety of Trevena's oliceridine therapy in patients for 48 hours following bunionectomy and 24 hours following abdominoplasty.
- [By Chris Lange]
Trevena Inc. (NASDAQ: TRVN) reported positive results from two late-stage clinical trials that work to treat post-surgical pain. The company intends to submit these results to the FDA for a marketing approval agreement in the fourth quarter. Previously, oliceridine was approved for a breakthrough designation by the agency.